ArticleScientific reports2026
Lung function trajectories and exacerbation risks in preserved ratio impaired spirometry (PRISm) patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Preserved ratio impaired spirometry (PRISm) is a heterogeneous, clinically relevant pre-chronic obstructive pulmonary disease (pre-COPD) state that remains incompletely understood. Recurrent exacerbations link to poor outcomes, but data on subtype-specific (lung function trajectory) exacerbation risk is scarce. This study assessed lung function trajectory changes and exacerbation risk in PRISm. We enrolled 204 PRISm patients and 501 individuals with normal lung function. Demographics, clinical features, and exacerbation events over the past year were evaluated. 204 PRISm patients were subsequently followed for one year, and categorized into three subgroups: PRISm-normal, persistent PRISm, and PRISm-COPD. Exacerbation events and lung function changes were analyzed. Univariate and multivariate logistic regression analyses were used to identify risk factors for exacerbation. PRISm patients had higher smoking prevalence, comorbidities, and symptom burden than controls (p < 0.05). The incidence of moderate and severe exacerbations and frequent exacerbations in PRISm patients were 1.8-fold (0.35 vs. 0.19, p < 0.001), 2.1-fold (0.17 vs. 0.08, p < 0.05), and 2.7-fold (10.3% vs. 3.8%, p < 0.001) higher than the normal group. The PRISm-COPD subgroup had the highest risk, with rates 3.7- to 7.7-fold higher than the normal group. Furthermore, persistent PRISm and PRISm-COPD subgroups showed significantly greater declines in forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and FEV1/FVC. After adjusting for confounders, the PRISm-COPD subgroup had a more pronounced FEV1 decline (− 27.2 ml/y vs. −30.5 ml/y, p < 0.001). Multivariate analysis showed that FEV1 decline was inversely associated with exacerbations in PRISm patients, whereas elevated C-reactive protein levels were positively correlated with exacerbation risk (p < 0.001). PRISm patients exhibit worse lung function and more frequent acute exacerbations, with the PRISm-COPD subtype predicting faster lung function decline. Worsening lung function and inflammation levels significantly increase exacerbation risk in PRISm patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.